14:53 EDT UroGen sinks 26% to $7.26 after FDA posts briefing docs for UGN-102
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on URGN:
- Positive Buy Rating for UroGen Pharma Driven by Promising UGN-102 Prospects and Strong Financial Position
- UroGen Pharma Reports Q1 2025 Earnings and Pipeline Progress
- UroGen Pharma’s Earnings Call: Progress and Challenges
- Urogen Pharma’s Promising Developments and High Approval Likelihood: A Buy Recommendation
- UroGen Pharma reports Q1 EPS (92c), consensus (80c)
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue